Wegovy Demand Busts Through Novo Nordisk’s Expanded Capacity
Novo Nordisk said it would temporarily reduce production of the lower starting dose of Wegovy even as a second contract manufacturer has come online in April.
You may also be interested in...
Supply of the obesity drug has outpaced demand in the US, and Novo Nordisk said that will persist throughout 2023.
Groups discuss need for chronic care of the condition as well as the importance of having all drugs for all conditions adequately labeled for patients at higher body weights.
Novo Nordisk’s new generation of GLP-1 products have led to never-before-seen rates of medication-induced weight loss but require a lifelong commitment from patients to maintain these results – a commitment the market may not be able to rely on, since patients have not generally tended to stay on GLP-1 medications long-term.